Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/2095
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGayathri Devi, D-
dc.contributor.authorCibin, T R-
dc.contributor.authorRamaiah, D-
dc.contributor.authorAnnie, A-
dc.date.accessioned2016-01-18T06:50:52Z-
dc.date.available2016-01-18T06:50:52Z-
dc.date.issued2008-
dc.identifier.citationJournal of Photochemistry and Photobiology B-Biology 92(3):153-159;18 Sep 2008en_US
dc.identifier.issn1011-1344-
dc.identifier.urihttp://ir.niist.res.in:8080/jspui/handle/123456789/2095-
dc.description.abstractPhotodynamic therapy (PDT) is based on the light-induced activation of a photosensitizer generating highly reactive oxygen species that induce tissue destruction in malignant tissues. The present study was carried out to assess the photosensitizing potential of bis(3,5-diiodo-2,4,6-trihydroxyphenyl)squaraine in PDT trials in vivo. Male Swiss albino mice were divided into five groups. Skin tumor was induced using 7,12-dimethylbenz(a)anthracene - DMBA in the animals of Groups II, III, IV and V, while animals of Group I served as the control. At the completion of 20 weeks of induction, the tumor bearing mice from Group III, IV and V were given an intraperitoneal injection with the squaraine dye (12.5 mg/kg body weight). After 24 h, in the Group IV and V animals, the tumor area was exposed to visible light from a 1000 W halogen lamp. The mice from groups I to IV were sacrificed two weeks after the PDT treatment and the marker enzymes (myeloperoxidase [MPO], beta-D-glucuronidase, rhodanese, lactate dehydrogenase [LDH], hexokinase, sialic acid and caspase) were assayed in tumor and normal tissues. Animals from Group V were sacrificed after 90 days of PDT treatment and the above parameters were recorded. Reduction in tumor volume and reversal of biochemical markers to near normal levels were observed in the treatment groups. The study assumes importance as it is the first report on PDT-a novel modality, using a squaraine dye for skin cancer therapy in vivo. The uniqueness of the mode of treatment lies in the selective uptake of squaraine dye by the cancer cells and their selective destruction using PDT without affecting the neighbouring normal cells, which is much advantageous over radiation therapy now frequently used. Also in skin cancer models, the progression/cure can be visualized by the naked eye which is another point of advantage, while seeking new modalities for the treatment of cancer.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectPhotodynamic therapyen_US
dc.subjectSquaraine dyeen_US
dc.subjectPhotosensitizeren_US
dc.subjectSkin tumoren_US
dc.subjectDMBAen_US
dc.subjectFluorescence emissionen_US
dc.subjectSquaraine chemistryen_US
dc.subjectInduced apoptosisen_US
dc.subjectMouse skinen_US
dc.subjectCarcinomaen_US
dc.subjectcarcinogenesisen_US
dc.titleBis(3,5-diiodo-2,4,6-trihydroxyphenyl)squaraine: A novel candidate in photodynamic therapy for skin cancer models in vivoen_US
dc.typeArticleen_US
Appears in Collections:2008

Files in This Item:
File Description SizeFormat 
2008_0165.pdf
  Restricted Access
345.35 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.